Correction: Targeting a ribonucleoprotein complex containing the caprin-1 protein and the c-Myc mRNA suppresses tumor growth in mice: an identification of a novel oncotarget

Ya-Qi Qiu; Cheng-Wei Yang; Yue-Zhi Lee; Ruey-Bing Yang; Chih-Hao Lee; Hsing-Yu Hsu; Chien-Chung Chang; Shiow-Ju Lee

doi:10.18632/oncotarget.27074

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Targeting a ribonucleoprotein complex containing the caprin-1 protein and the c-Myc mRNA suppresses tumor growth in mice: an identification of a novel oncotarget

PDF | How to cite

Oncotarget. 2019; 10:4919-4919. https://doi.org/10.18632/oncotarget.27074

Metrics: PDF 1471 views | ?

Ya-Qi Qiu^1,2, Cheng-Wei Yang¹, Yue-Zhi Lee¹, Ruey-Bing Yang³, Chih-Hao Lee⁴, Hsing-Yu Hsu¹, Chien-Chung Chang² and Shiow-Ju Lee¹

¹ Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli, Taiwan
² Graduate Program of Biotechnology in Medicine, Institute of Molecular & Cellular Biology, National Tsing Hua University, Hsinchu, Taiwan
³ Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
⁴ Department of Genetics and Complex Diseases, Division of Biological Sciences, Harvard School of Public Health, Boston, Massachusetts, USA

Published: August 06, 2019

This article has been corrected: During manuscript editing according to the reviewers' comments, the tubulin control for cyclin D1 in Figure 4A right panel was accidentally misplaced. The corrected Figure 4A is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2015; 6:2148–2163. DOI: https://doi.org/10.18632/oncotarget.3236.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27074

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Targeting a ribonucleoprotein complex containing the caprin-1 protein and the c-Myc mRNA suppresses tumor growth in mice: an identification of a novel oncotarget